A股辅助生殖板块持续走强，福元医药盘中创历史新高，共同药业、汉商集团、利德曼涨停，安科生物 涨超15%，广生堂涨超10%，新光药业、达嘉维康、贝因美、星昊医药、贝瑞基因跟涨。 ...

Group 1 - The A-share innovative drug concept stocks continue to rise, with Nanxin Pharmaceutical hitting the 20% daily limit up [1] - Qizheng Tibetan Medicine and Hanshang Group also reached the daily limit up, indicating strong market interest [1] - Other companies such as Hitec Biological, Anke Biological, Huisheng Biological, Zhendong Pharmaceutical, Tebao Biological, and Treasure Island saw increases of over 5% [1]

（文章来源：每日经济新闻） 每经AI快讯，7月31日，创新药概念股持续活跃，南新制药20%涨停，奇正藏药、汉商集团涨停，海特 生物、安科生物、回盛生物、振东制药、特宝生物、珍宝岛等涨超5%。 ...

格隆汇7月31日｜A股创新药概念股继续上涨，其中，南新制药20CM涨停，奇正藏药、汉商集团涨停， 海特生物、安科生物、回盛生物、振东制药、特宝生物、珍宝岛等涨超5%。 ...

人民财讯7月31日电，辅助生殖概念大涨，共同药业（300966）、利德曼（300289）20%涨停，安科生 物（300009）涨逾12%，汉商集团（600774）涨停，达嘉维康（301126）、广生堂（300436）等大涨。 ...

Investment Rating - The report rates the mother and baby consumption industry as "Overweight" [2][9] Core Insights - The introduction of a national childcare subsidy of 3,600 yuan per child per year, totaling up to 10,800 yuan per child, is expected to improve consumption expectations in the mother and baby sector [3] - The report highlights that despite a decline in birth rates over the past seven years, the overall mother and baby market has experienced a compound annual growth rate (CAGR) of over 15% from 2018 to 2024 due to consumption upgrades and refined parenting [3] - The report emphasizes the rise of domestic brands in the mother and baby sector, with significant market share gains and a return of industry influence to local brands [3] Summary by Sections National Childcare Subsidy - The national childcare subsidy program will start on January 1, 2025, providing cash subsidies to families with children under three years old, with a basic standard of 3,600 yuan per year [3] - Local governments are expected to introduce additional subsidies, creating a wave of local support for childbirth [3] Market Growth and Opportunities - The mother and baby market is projected to rebound due to improved policies and an anticipated increase in birth rates in 2024 [3] - Key sectors and companies recommended for investment include: - Fertility and reproductive health: Focus on companies like Jinxin Reproductive and Livzon Pharmaceutical [3] - Infant nutrition: Recommendations include China Feihe and Yili Group [3] - Baby appliances: Suggested investment in Bear Electric [3] - Apparel and home textiles: Companies like Semir and Anta are highlighted [3] - Baby care products: Brands such as Runben and New Page are recommended [3] Valuation Table - The report includes a valuation table with various companies in the mother and baby sector, indicating their stock prices, market capitalization, and profit forecasts for 2025, 2026, and 2027, along with corresponding investment ratings [4]

法律意见书 法律意见书 安徽天禾律师事务所 关于 安徽安科生物工程（集团）股份有限公司 2025 年第二次临时股东大会 之 法律意见书 安徽天禾律师事务所 关于安徽安科生物工程（集团）股份有限公司 2025 年第二次临时股东大会 之法律意见书 致：安徽安科生物工程（集团）股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以 下简称"《股东会规则》"）、《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等法律、法规及规范性文件的规定，安徽天 禾律师事务所（以下简称"天禾"或"本所"）指派陶闰岳、朱华耀律师出席 了安徽安科生物工程（集团）股份有限公司（以下简称"安科生物"或"公司"） 2025 年第二次临时股东大会（以下简称"本次股东大会"），对本次股东大会 的合法性进行见证并出具法律意见。 本所及经办律师依据《证券法》《律师事务所从事证券法律业务管理办法》 和《律师事务所证券法律业务执业规则（试行）》等规定及本法律意见书出具 日以前已经发生或者存在的事实，严格履行了法定职责，遵循了勤勉尽责和 ...

证券代码：300009 证券简称：安科生物 公告编号：2025-038 安徽安科生物工程（集团）股份有限公司 2025 年第二次临时股东大会决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 特别提示： 1、本次股东大会无否决议案的情形； 2、本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开时间 现场会议召开时间：2025 年 7 月 28 日（星期一）上午 09:30 网络投票时间： （2）通过深圳证券交易所互联网投票系统投票的具体时间为：2025 年 7 月 28 日 09:15 至 7 月 28 日 15:00 期间的任意时间。 2、现场会议地点：合肥市高新区海关路 K-1 安徽安科生物工程（集团）股 份有限公司（以下简称"公司"） A 座 1201 会议室 3、召开方式：本次股东大会采取现场表决与网络投票相结合的方式召开。 4、会议召集人：公司董事会 5、会议主持人：公司董事长宋礼华先生 6、会议的召集、召开与表决程序符合有关法律法规、行政法规、部门规章、 规范性文件和《公司章程》等相关规定。 ...

Group 1: Company Strategy and Goals - The overall business goal for 2025 is to achieve restorative growth and maintain stable development [3] - The company aims to enhance the sales proportion of growth hormone water injections and expand the indications for growth hormone [3] - The company plans to accelerate the production capacity of the cancer drug Trastuzumab (Ansatin) and deepen brand building and market expansion [3] Group 2: Product Development and Clinical Trials - The clinical trial for "AK2017 Injection" (recombinant human growth hormone-Fc fusion protein injection) has successfully completed Phase II enrollment, with discussions for Phase III trial already held [3] - The company is actively promoting clinical trials for interferon spray and inhalation agents, targeting respiratory infections and gynecological diseases [3] - The "AK1008 Project" (human interferon α2b spray) is in Phase II trials for treating viral infections in children [3] Group 3: Competitive Landscape - Currently, there are 5 companies producing short-acting growth hormones, and several companies are expected to launch long-acting growth hormones [4] - The market for growth hormones is competitive but the overall pricing system remains stable [4] - The strategic partnership with Weisheng Pharmaceutical aims to cover the long-acting growth hormone market and enhance the company's competitiveness in children's growth and development [7] Group 4: Innovation and Collaborations - The company is developing several innovative drugs, including "HuA21 Injection" targeting HER2, which has shown promising safety and efficacy in early trials [4] - Collaboration with Afana Company on "AFN0328 Injection" for HPV precancerous lesions is in Phase I trials, with plans for further mRNA drug development [5] - The company is also involved in CAR-T cell therapy research through its investment in Boshengji Company, which has received implicit approval for clinical trials [5] Group 5: Market Expansion and Future Plans - The company is preparing to expand its international market presence by building FDA and EU-compliant production lines and engaging with foreign distributors [8] - The exclusive agency agreement with Baoji Pharmaceutical for the innovative drug "SJ02" aims to enhance the company's product matrix in the assisted reproduction field [8] - The company anticipates that the launch of long-acting growth hormones and long-acting follicle-stimulating hormones will provide new growth points for its business [8]

Core Viewpoint - The legal opinion letter from Anhui Tianhe Law Firm confirms the compliance and legality of Anhui Anke Biotechnology (Group) Co., Ltd.'s fourth employee stock ownership plan, indicating that the company meets all necessary legal requirements for implementation [2][4][16]. Group 1: Company Qualifications - Anhui Anke Biotechnology is a legally established joint-stock company, having been approved for its initial public offering and listing on the Growth Enterprise Market in 2009 [5]. - The company is currently in good standing and does not face any legal or regulatory issues that would necessitate its termination, thus qualifying for the employee stock ownership plan [5][16]. Group 2: Legality and Compliance of the Employee Stock Ownership Plan - The employee stock ownership plan adheres to the principles of legality, voluntary participation, and risk-bearing by employees, as outlined in the relevant regulatory guidelines [6][7]. - The plan's participants will include key management and core personnel from the oncology division, with a maximum of 37 individuals, ensuring compliance with the guidelines regarding participant selection [7]. - Funding for the plan will come from employees' legal salaries and self-raised funds, aligning with regulatory requirements [7][8]. - The plan stipulates a holding period of 12 months for lock-up followed by a 60-month unlocking period, which is consistent with regulatory standards [8][9]. Group 3: Management and Governance of the Plan - The management of the employee stock ownership plan will be conducted internally, with a management committee elected by the participants, ensuring proper governance and protection of participants' rights [9][10]. - The plan allows for adjustments in participant lists based on actual contributions, maintaining flexibility in management [7][10]. Group 4: Legal Procedures and Information Disclosure - The company has completed the necessary legal procedures for the plan, including board and supervisory committee approvals, and is preparing for a shareholder meeting to finalize the plan [13][16]. - The company has fulfilled its information disclosure obligations regarding the plan, with announcements made in accordance with regulatory requirements [15][16]. Group 5: Conclusion and Future Steps - The legal opinion concludes that the company is qualified to implement the employee stock ownership plan, which complies with all relevant regulations and has undergone the necessary approval processes [16][17]. - The plan will require further approval from the shareholders' meeting, which must be passed by a majority of non-related shareholders [13][16].